The neuropeptide galanin regulates numerous physiological activities in the body, including feeding and metabolism, learning and memory, nociception and spinal reflexes, and anxiety and related behaviors. Modulation of blood glucose levels by suppressing insulin release was the first reported activity for galanin. This inhibition was mediated by one or more pertussis toxin-sensitive G proteins of the G i/o subfamily. However, the molecular identities of the specific G protein(s) and intracellular effectors have not been fully revealed. Recently, we demonstrated that mice lacking G o 2, but not other members of the G i/o protein family, secrete more insulin than controls upon glucose challenge, indicating that G o 2 is a major transducer for the inhibitory regulation of insulin secretion. In this study, we investigated galanin signaling mechanisms in β cells using cell biological and electrophysiological approaches. We found that islets lacking G o 2, but not other G i/o proteins, lose the inhibitory effect of galanin on insulin release. Potentiation of ATPsensitive potassium (K ATP ) and inhibition of calcium currents by galanin were disrupted by anti-G o 2α antibodies. Galanin actions on K ATP and calcium currents were completely lost in G o 2 −/− β cells.
The neuropeptide galanin regulates numerous physiological activities in the body, including feeding and metabolism, learning and memory, nociception and spinal reflexes, and anxiety and related behaviors. Modulation of blood glucose levels by suppressing insulin release was the first reported activity for galanin. This inhibition was mediated by one or more pertussis toxin-sensitive G proteins of the G i/o subfamily. However, the molecular identities of the specific G protein(s) and intracellular effectors have not been fully revealed. Recently, we demonstrated that mice lacking G o 2, but not other members of the G i/o protein family, secrete more insulin than controls upon glucose challenge, indicating that G o 2 is a major transducer for the inhibitory regulation of insulin secretion. In this study, we investigated galanin signaling mechanisms in β cells using cell biological and electrophysiological approaches. We found that islets lacking G o 2, but not other G i/o proteins, lose the inhibitory effect of galanin on insulin release. Potentiation of ATPsensitive potassium (K ATP ) and inhibition of calcium currents by galanin were disrupted by anti-G o 2α antibodies. Galanin actions on K ATP and calcium currents were completely lost in G o 2 −/− β cells.
Furthermore, the hyperglycemic effect of galanin is also blunted in G o 2 −/− mice. Our results demonstrate that G o 2 mediates the inhibition of insulin release by galanin by regulating both K ATP and Ca 2+ channels in mice. Our findings provide insight into galanin's action in glucose homeostasis. The results may also be relevant to the understanding of galanin signaling in other biological systems, especially the central nervous system. glycemia | GTP-binding protein-coupled receptor | heterotrimeric | signal transduction | Alzheimer's disease G alanin, a 29-to 30-residue neuropeptide hormone initially discovered in porcine intestine (1) , is distributed throughout the central and peripheral nervous systems and the intestinal neuroendocrine system of many mammalian species (2, 3) . The first 15 N-terminal amino acids, which retain the biological activity of the full-length peptide hormone, are highly conserved, underscoring a physiological importance across species. Galanin coexpresses and colocalizes with many neurotransmitters (4) and functions as an inhibitory modulator.
The biological effects of galanin are mediated by galanin receptors. Three types of galanin receptors (GalR1, GalR2, and GalR3) have been identified by molecular cloning and characterized pharmacologically in various species (5) (6) (7) (8) . All three subtypes of galanin receptors are members of the GTP-binding protein-coupled receptor (GPCR) superfamily. The three galanin receptors exhibit overlapping but distinctive patterns of expression in the central nervous system and periphery. The distinct distribution patterns of receptors support the notion that each receptor mediates some unique physiological function in the body.
Physiological Effects of Galanin. The biological activity of galanin has been studied intensively in the central and peripheral nervous systems, as well as in the pituitary and the endocrine system. Galanin signaling is involved in feeding and metabolism, learning and memory, nociception and spinal reflexes, anxiety, neuron regeneration, and the pathogenesis of Alzheimer's disease (9) (10) (11) (12) . The precise role of galanin signaling in these states has not been elucidated. The first reported biological activity of galanin was its effect on plasma glucose levels in dogs and rats (1) . The pancreas is highly innervated, and galanin localizes to autonomic nerve terminals in the endocrine pancreas (3) as well as to nerve cell bodies in the celiac ganglion (13) . Infusion of galanin into animals results in a significant increase of blood glucose levels by inhibition of insulin secretion from pancreatic β cells (1, 14) . Infusion of galanin directly into animals through the pancreatic artery at a concentration that is similar to that released from stimulated pancreatic nerve termini is sufficient to inhibit insulin secretion (15) . Conversely, a galanin antagonist can block galaninmediated inhibition of insulin release from islets (16) . In galanindeficient animals, the inhibition of insulin secretion induced by the chemical activation of sympathetic nerves was observed to be impaired (17) . Interestingly, genetically obese ob/ob mice have severely decreased pancreatic content of galanin of less than 10% of levels found in control animals (18) . In addition, the number of galanin immunoreactive cells is dramatically reduced in diabetic animals (19) . Reduced islet innervation has been associated with impaired insulin secretion in type II diabetic hamsters (20) . These results suggest that pancreatic galaninergic nerve dysfunction may contribute to the development of type II diabetes, which is an increasing worldwide public health problem.
Galanin-Receptor Signal Transduction. The signaling mechanisms of GalR1 and GalR3, which are coupled to their effectors by pertussis toxin (PTX)-sensitive G i/o G proteins, have been pharmacologically studied. Stimulation of receptors expressed in transfected cell lines or oocytes can inhibit forskolin-stimulated cAMP production, or activate G protein-regulated inwardly rectifying K + channels in a PTX-sensitive manner (5, 7, 21, 22) . Multiple subclasses of G proteins may be involved in GalR2 signaling (6, (22) (23) (24) . GalR2 can activate phospholipase C and protein kinase C via G q/11 and activate MAPK and/or inhibit forskolin-stimulated cAMP production through PTX-sensitive G i/o G proteins. Like the galanin receptors, all five nonsensory PTX-sensitive G i/o members are expressed in neurons and endocrine tissues. The signal transduction mechanisms mediating galanin's physiological effects have not been studied in native tissue or primary cells. Our previous studies demonstrated that all nonsensory members of the PTX-sensitive G i /G o protein family, namely G i 1, G i 2, G i 3, G o 1, and G o 2, are expressed in pancreatic islets, and that only G o 2, and not G i 1-3 or G o 1, G protein-deficient mice show an "improved" glucose tolerance test and enhanced insulin release from pancreatic β cells (25) . This suggests that G o 2 is the major transducer mediating inhibitory effects on insulin release that prevent oversecretion. In this study, using G i / G o α-subunit gene knockout animals established in our laboratory (26, 27) , we demonstrate that the G o 2 G protein mediates galanin's inhibitory effect on insulin release. We also identify potentiation of ATP-sensitive potassium (K ATP ) currents and inhibition of Ca 2+ channels as possible molecular mechanisms mediating galanin-GalR-G o 2 signaling.
Results and Discussion
Inhibition of Insulin Release by Galanin Is Lost in G o 2α −/− Islets. In the present study, we addressed the possible molecular mechanisms by which galanin inhibits insulin release. Galanin has been shown to elevate blood glucose levels by inhibiting insulin release. PTX blocks the inhibitory effects of galanin, suggesting the involvement of G i /G o proteins in the process. PTX ADP ribosylates a cysteine at the carboxyl termini (−4 position) of the α subunits of G i/o G proteins and collectively blocks all G i /G o signaling. Therefore, PTX assays cannot delineate through which specific G protein(s) galanin signals. To investigate the mechanism and to screen the responsible G i /G o protein(s) for mediating the inhibition of insulin release by galanin, we established a perifusion assay of isolated islets from G i /G o -deficient animals aimed at identifying which G i /G o protein(s) mediates galanin's inhibitory effects. A pool of 30-50 islets isolated shortly after a recovery period were placed onto a nylon membrane in a perifusion chamber. After 60 min of perifusion with 1.8 mM glucose in Krebs Ringer bicarbonate (KRB) solution to establish a stable rate of insulin secretion, the glucose concentration in the buffer was elevated to 16.2 mM and islets were continually perifused for 120 min at this high-glucose concentration. The perifusion solution was then switched back to 1.8 mM (low) glucose for 30 min, followed by perifusion with KCl (30 mM) for an additional 30 min. During the high-glucose (16.2 mM) perifusion period, galanin (100 nM) was included transiently (from minute 60 to 90) in the buffer. Fig. 1 shows insulin secretion profiles of islets isolated from WT and knockout mice lacking G i 2α, G i 1/G i 3α, G o 1α, and G o 2α. High glucose (16.2 mM) induced insulin release from pancreatic islets effectively from all of the genotypes. When the lower-glucose (1.8 mM) buffer was applied, insulin release from islets declined to basal levels. KCl (30 mM), which directly depolarizes the β-cell membrane, triggered insulin release from islets. Galanin (perifused together with high glucose) suppressed insulin secretion in islets from WT, G i 1α
, and G o 1α −/− mice. Upon removal of galanin from the buffer, insulin secretion resumed at the elevated rates. In contrast, the inhibitory effect of galanin on insulin release was absent in islets from G o 2α −/− mice. The results indicate that G o 2 mediates the inhibitory effect of galanin on insulin release in pancreatic β cells. The levels of insulin released under basal, glucose-stimulated, and K + -induced conditions were comparable for islets from WT, G i 2α
mice, but were significantly higher for islets from G o 2α −/− (P < 0.01). This suggests that, in addition to mediating galanin inhibition of insulin release, G o 2 modulates the sensitivity of islets to glucose and maybe directly or indirectly regulates secretory machinery.
K ATP Channels in G o 2α
−/− Islets Show Normal Glucose Sensitivity. It is well-established that glucose and other nutrients promote the depolarization of the β-cell membrane and Ca 2+ influx through voltage-dependent channels. This constitutes the principal stimulus for insulin exocytosis (28) . A glucose transporter (Glut-2) in the β cell facilitates entry of glucose into the cell (29) . The enzyme glucokinase phosphorylates glucose to glucose-6-phosphate.
Glucokinase appears to function as the fundamental glucose sensor that controls the subsequent β-cell response (30) . Glucose is oxidized, leading to a rapid increase of the concentration of intracellular ATP and a decrease of the concentration of ADP. This in turn changes the ATP:ADP ratio in the β cell. ATP is a potent inhibitor of the ATP-sensitive K + channel, whereas ADP is a stimulator of the channel (31, 32) . Inhibition of K + channels by ATP decreases K + efflux from the β cell, thus leading to membrane depolarization (33) . Depolarization opens voltagedependent Ca 2+ channels, causing a rapid increase in the concentration of intracellular Ca 2+ . This triggers exocytosis of pancreatic β-cell insulin granules (34) . As observed, galanin can inhibit insulin secretion from pancreatic β cells in a PTX-sensitive manner. To investigate whether the G o 2-mediated signaling pathway regulates K ATP and Ca 2+ channels, we studied channel properties via patch-clamp recording. First, the integrity of K ATP channels was investigated in β cells from G o 2α knockout mice. Specifically, K ATP channels were studied in response to glucose (Fig. S1 ). Freshly isolated islets were digested briefly with trypsin to generate single β cells. Short-term cultured β cells were used in the studies. Glucose inhibited K ATP currents in β cells from both wild-type and G o 2α −/− (Fig. S1 A-C) . High glucose (16.2 mM) inhibited K ATP currents in isolated β cells from −58.0 ± 15.6 to −22 ± 6.1 pA/pF for WT (n = 10, P < 0.01) and −49.8 ± 13.3 to −27.1 ± 5.1 pA/pF for G o 2α −/− (n = 12, P < 0.05) mice (Fig. S1D) . Furthermore, glucose deprivation stimulated K ATP currents in both WT (−26.5 ± 5.0 to −62.6 ± 13.5 pA/pF; n = 9, P < 0.01) and G o 2α −/− mice (−22.26 ± 4.0 to −65.34 ± 14 pA/pF; n = 6, P < 0.01). This result demonstrates that K ATP channels in β cells isolated from G o 2α −/− mice respond to glucose similarly to WT controls and suggests that lack of G o 2α does not alter the responsiveness of K ATP channels to glucose in β cells. −/− mice were recorded in the absence of galanin, presence of 100 nM galanin, or 50 μM diazoxide. As shown in Fig. 2 , the averages of glucose-sensitive K ATP currents in β cells from WT mice were −35.4 ± 6.3 and −58.0 ± 10.7 pA/pF (n = 12) before and after application of 100 nM galanin to the bath solution, respectively. The averages of K ATP currents in G o 2α −/− β cells were −46.5 ± 6.7 and −45.3 ± 6.9 pA/pF (n = 11) before and after application of 100 nM galanin to the bath solution, respectively (Fig.  2) . Diazoxide, a selective K ATP channel opener, was able to further potentiate the channels in both WT and G o 2α −/− β cells in the presence of galanin. Galanin significantly enhanced (P < 0.01) K ATP currents in β cells from WT control mice; however, this current augmentation was completely absent in the β cells from G o 2α −/− mice. The results suggest that G o 2 protein mediates the inhibitory effect of galanin on K ATP channels in mouse β cells, and that the potentiation of K ATP by diazoxide is independent of the G o 2-mediated pathway. These data are consistent with the existence of a specific signaling mechanism whereby the inhibitory neuropeptide galanin binds to its receptors and activates K ATP channels through G o 2 to inhibit insulin secretion from β cells.
Anti-G o 2α Antibodies Suppress Basal K ATP Currents and Abolish the Potentiating Effects of Galanin on K ATP in WT β Cells. To further validate that G o 2 G protein is a critical component in the inhibitory pathway mediating galanin signaling, we used affinitypurified anti-G o 2α antibodies to titrate the endogenous G o 2α protein and tested K ATP current activity in islet β cells. WT β cells dialyzed with anti-G o 2α antibodies showed a reduced basal K ATP channel activity. After rupture of the patch, antibodies diffused into the cells from the holding pipettes, and the K ATP current decreased from −43.7 ± 0.7 to −15.7 ± 0.1 pA/pF (n = 5, P < 0.01) within 10 min and reached a new steady state. K ATP currents were stable when the holding pipettes contained nonspecific IgG or no antibodies. Galanin (100 nM) was perifused into the cell chamber during the steady phase. As expected, K ATP currents were not enhanced by galanin in β cells dialyzed with anti-G o 2α antibodies. Notably, the antibodies had no effects of the K ATP channel opener diazoxide on β cells (Fig. 3) . These findings are in agreement with studies on isolated β cells from G o 2α −/− mice (Fig. 2) , and confirm that G o 2 is a critical downstream signal transducer of galanin receptors in β cells. Through modulation of K ATP channel activity, G o 2 regulates insulin secretion. The stimulation of K ATP channels by galanin was abolished by dialyzing anti-G o 2α antibodies into β cells (Fig. 3 A and B) . Thus, antibodies dialyzed into the cytoplasm appear to titrate G o 2 away from their effectors and change the dynamic regulation of effectors. The reduction of the basal K ATP channel activity by anti-G o 2α antibodies suggests that under basal conditions, G o 2 potentiates K ATP channel activity in β cells. The K ATP channels in β cells are involved in maintaining membrane potential, and activation of K ATP channels is required for retaining β cells in the hyperpolarized state to suppress insulin secretion. In addition, the observation of dynamic changes in K ATP activity by dialyzed anti-G o 2α antibodies suggests that the α subunit may be involved directly. Our results from native channel studies are also in agreement with previous findings that demonstrated that the activity of cloned SUR1-Kir6.2 channels (pancreatic form) can be enhanced by a G i/o α protein during inside-out patch recordings in a reconstitution assay (35) . In addition, recombinant G o α protein can potentiate neuronal (brain) K ATP channel activity in inside-out patches (36) . Taken together, these results support that the α subunit of G o also participates in the regulation of K ATP channel activity. 2+ current in β cells isolated from WT mice, with a decrease of 55% of peak currents from −108.93 ± 25.68 to −60.26 ± 17.96 pA/pF (n = 8, P < 0.01) (Fig. 4 B and C) . When the cells were dialyzed with anti-G o 2α antibodies, the average peak currents were −85.13 ± 21.58 and −72.07 ± 26.41 pA/pF (n = 8) before and after galanin (100 nM) application, respectively. No significant difference was observed before and after application of galanin in the presence of anti-G o 2α antibodies. This demonstrates that anti-G o 2α antibodies can block the inhibitory effect of galanin on Ca 2+ currents. These observations suggest that in addition to modulating K ATP channel activities, G o 2 protein could also mediate effects of galanin by regulating the activity of the pancreatic L-type Ca 2+ channel. To confirm this hypothesis, we performed patch-clamp recordings of Ca 2+ channel activity of β cells isolated from G o 2α −/− animals. In G o 2α −/− β cells, average peak currents before and after application of galanin were −51.87 ± 11.9 and −38.54 ± 15.6 pA/pF (n = 6), respectively. There was also no statistically significant difference before and after application of galanin. These results show that the lack of G o 2α in β cells by gene knockout or titration of G o 2α by antibodies leads to the loss of galanin's inhibitory effect on Ca 2+ channels. It is noteworthy that there is a statistically significant difference (P < 0.05) in the Ca 2+ currents in WT and G o 2α −/− β cells. The cause for this reduction of Ca 2+ channel activity in G o 2α knockout is currently unknown. Taken together, our results suggest that G o 2 mediates the potentiation of K ATP channels and inhibition of Ca 
Loss of G o 2α Blunts the Hyperglycemic Effect of Galanin in Vivo.
To confirm our findings that G o 2 mediates galanin receptor signaling in pancreatic β cells and galanin's inhibitory effect on insulin secretion, we tested the effect of galanin administration to G o 2α −/− and WT mice on their blood glucose levels. Galanin can effectively suppress insulin release from β cells; therefore, administration of galanin into the bloodstream will suppress insulin levels, and in turn increase blood glucose levels. Galanin (2 μg/kg) was delivered via the retroorbital vein in overnight-fasted mice. Blood glucose levels were monitored before and after administration of galanin. As shown in Fig. 5 , galanin elevates blood glucose levels rapidly, reaching a maximum after 10 min in WT mice and declining slowly thereafter. In WT mice, blood glucose levels were raised from a basal level of 74.5 ± 3.4 mg/dL to 130.1 ± 7.4 mg/dL 10 min postinjection and 121.8 ± 5.7 mg/dL 20 min postinjection. These correspond to a 77.8 and 64.5% increase after administration of galanin, respectively. In contrast, galanin only elevated glucose levels slightly over basal levels in G o 2α-null mice. The basal blood glucose level of G o 2-null mice was 60.4 ± 1.7 mg/dL. The glucose levels were raised moderately after galanin injection to 85.5 ± 3.1 mg/dL 10 min postinjection and 81.8 ± 3.7 mg/dL 20 min postinjection, corresponding to a 45.7 and 36.9% increase over basal, respectively. The results demonstrate that galanin can effectively elevate blood glucose levels in WT mice, and that this effect is significantly reduced (P < 0.01) in mice lacking G o 2α. This suggests that G o 2 mediates a critical signaling pathway for galanin in the modulation of glucose homeostasis in the body. We did not observe a complete loss of galanin's hyperglycemic effect in G o 2α-null mice, suggesting that galanin may also use other, G o 2-independent mechanisms to augment glucose levels in β cells. In fact, galanin has been shown to enhance plasma glucagon levels secreted from pancreatic α cells. During the systemic infusion of galanin, pancreatic glucagon output rapidly doubled in dogs and mice (3, 39) . Therefore, galanin-induced hyperglycemia is the additive action of lowering basal plasma insulin levels, increasing basal plasma glucagon levels, and possibly other mechanisms. Increasing plasma glucagon by galanin is believed to be mediated by G 11/q proteins, but not by G i/o proteins. Therefore, elevation of blood glucose levels by the action of glucagon should not be affected in G o 2α −/− mice. Physiologically, the body responds to hypoglycemia by increasing glucose production and decreasing glucose sequestration (by reducing insulin levels) simultaneously.
The distribution of galanin suggests that it is a neuropeptide. Its activity is exerted locally, rather than systemically as a humoral agent (40) . Pancreatic islets are highly innervated, and activation of pancreatic nerves is sufficient to influence islet function (15) . G o was originally identified as the "other" PTXsensitive G protein in the brain and is highly expressed in the CNS and endocrine cells (41) . Logically, antagonizing the G s pathway by suppressing adenylyl cyclase (AC) activity might be a mechanism for galanin receptor-G o protein-mediated signaling in cells. Galanin can inhibit AC activity through G i 3 (42) or G i 2/ G i 3 proteins in the RINm5F cell line (43) . However, galanin can still suppress insulin release from insulin-secreting cells in the presence of cAMP in the media (44) . Using static islet incubation assays, we also confirmed that the suppression of insulin release by galanin is not dependent on the AC-cAMP pathway. Islets were incubated with or without galanin in the presence of 0.1 mM dibutyryl-cAMP and 16.2 mM glucose, and released insulin was measured. Galanin can inhibit insulin release from wild-type islets even in the presence of cAMP, as observed previously (45) . This observation suggests that inhibiting AC and reducing cAMP levels are unlikely to be a mode for suppressing insulin release by galanin. In fact, G o is at best a poor AC inhibitor in vitro compared with G i proteins (46) . In addition, cellular cAMP levels are not elevated in G o −/− islets (47) . Taken together, reducing cAMP levels by inhibiting AC activity in β cells does not appear to constitute a major route for the inhibitory effect of galanin on insulin release.
Our findings can be summarized as follows: (i) The inhibitory effects of galanin on insulin release are lost in β cells from Galanin inhibits Ca 2+ -induced insulin release from permeabilized RINm5F cells in a PTX-sensitive manner (48), suggesting that direct inhibition of exocytosis is one mechanism of action for galanin. Constitutively active α subunits of G i/o protein can inhibit the exocytosis process, suggesting α subunits can directly influence the process (49) . In addition, enhanced potassium-induced insulin release in G o 2 −/− islets shown in Fig. 1 and our previous study (25) supports the notion that G o 2 may act on the insulin exocytosis process directly. Interestingly, Gβγ can also regulate the exocytosis process. Gβγ can bind SNAP-25 directly, as demonstrated in in vitro assays (50) . The C terminus of SNAP-25 may be a target of Gβγ for presynaptic inhibition (51) . Recently, it has been reported that norepinephrine can block the exocytosis process via the Gβγ subunit, and that this process is mediated specifically by Gα i 1/2 (52). Through study of G-protein knockout mice, we and others have observed that the expression levels of Gβγ correlate well with α-subunit levels in cells; Gβγ are down-regulated in α-subunit knockout and heterozygous mice (53) . This suggests that signaling through Gα and Gβγ is wellcoordinated in the cells. The mechanism for G-protein inhibition of the exocytosis process remains to be further elucidated.
Galanin has been shown to be an important neuropeptide that regulates glucose homeostasis in the body (17) . Our study demonstrates that galanin inhibition of insulin release is mediated mainly by G o 2, not other G i /G o proteins in pancreatic β cells. Other G i or G o proteins cannot compensate for the loss of G o 2 in mediating galanin's modulation of insulin secretion. This indicates that galanin receptors preferentially couple to effectors by G o 2 protein in β cells in vivo. At the molecular level, loss of G o 2 protein in β cells results in impairment of galanin's modulation of K ATP and Ca 2+ channels. This suggests in the insulin secretion pathway that galanin achieves its inhibitory effects on insulin release by at least at three different action sites: by potentiating K ATP channels, inhibiting L-type Ca 2+ currents, and regulating the exocytosis process. Inhibitory pep- : n = 18, 60.4 ± 1.7 (basal at 0 min), 85.5 ± 3.1 (10 min, increased 45.7% ± 5.7), 81.8 ± 3.7 (20 min, increased 36.9% ± 6.7). For the control no-galanin injection experiment, n = 6 and 8 for WT and G o 2α −/− mice, respectively. *P < 0.01; statistical significance was determined using the Student's t test from unpaired data or analysis of variance.
tide hormones play a critical role in maintaining euglycemia by preventing oversecretion of insulin into the bloodstream. Oversecretion of insulin could result in hypoglycemia that may impair the normal biological function of the endocrine and nervous systems. Furthermore, prolonged oversecretion of insulin may desensitize peripheral tissues and lead to the development of insulin resistance characteristic of type II diabetes.
Materials and Methods
All procedures were designed and performed in accordance with the generally accepted ethical standards for animal experimentation and approved by the Chancellor's Animal Research Committee of the University of California, Los Angeles. Detailed methods for islets and β-cell isolations, islet perifusion, electrophysiological recordings, and in vivo tests for galanin effects on glucose levels are described in SI Materials and Methods. Statistical analyses were done using paired and unpaired Student's t tests and analyses of variance in conjunction with Newman-Keuls tests where appropriate. Group differences at the level of P < 0.05 were considered statistically significant.
